paromomycin (humatin) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Paromomycin is a broad spectrum aminoglycoside antibiotic produced by by Streptomyces rimosus var. paromomycinus and used to treat intestinal infections such as cryptosporidiosis and amoebiasis, and other diseases such as leishmaniasis. Paromomycin is also used for the management of hepatic coma as adjunctive therapy. Paromomycin inhibits protein synthesis by binding to bacterial or protozoal 16S ribosomal RNA which causes defective polypeptide chains to be produced. Continuous production of defective proteins eventually leads to bacterial death. Gastrointestinal side effects include nausea, vomiting, diarrhea, and abdominal discomfort.   NCATS

Chemistry

  • SMILES: NC[C@@H]1O[C@H](O[C@H]2[C@@H](O)[C@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)O[C@@H]2CO)[C@H](N)[C@@H](O)[C@@H]1O
  • InChIKey: UOZODPSAJZTQNH-LSWIJEOBSA-N
  • Mol. Mass: 615.63
  • ALogP: -8.86
  • ChEMBL Molecules:
    paromomycin  
    paromomycin sulfate  
More Chemistry

Pharmacology

Alternative names

(1r,2r,3s,4r,6s)-4,6-diamino-2-{[3-o-(2,6-diamino-2,6-dideoxy-beta-l-idopyranosyl)-beta-d-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2-amino-2-deoxy-alpha-d-glucopyranoside | ameparomo | aminosidin | aminosidine | aminosidine sulfate | catenulin | crestomycin | crestomycin sulfate | estomycin | estomycin sulfate | gabbroral | gentamicin sulfate mixture with paromomycin sulfate | humatin | hydroxymycin | liposomal paromomycin | monomycin | monomycin a | neomycin e | neosporin | paramomycin | parmomycin | paromomicina | paromomycin | paromomycine | paromomycin i | paromomycin sulfate | paromomycin sulphate | paromomycinum | paromycin | paucimycin | paucimycinum | polysporin | wr279,396 | zygomycin a1

Organizations (44)

Research & Development (40)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (9)

Approved Indications (3)


 

Amebiasis (approved 2007)

Hepatic Encephalopathy (approved 2007)

Infections

Experimental Indications - Clinical Trial Phases 1-4 (6)


 

Cryptosporidiosis (Phase 2)

HIV Infections (Phase 2)

Leishmania (Phase 2)

Leishmaniasis, Cutaneous (Phase 3)

Leishmaniasis, Visceral (Phase 4)

Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 33
  • # of Trial Organizations: 40

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue